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Abstract: The F10 is a new commercially available scanning laser confocal ophthalmoscope 
(SLO) that can perform multiple functions. We determined the usefulness of noninvasive evalu-
ation of proliferative diabetic retinopathy (PDR) pathologies before and after intravitreal injec-
tion of bevacizumab (IVB) using the new indirect viewing system of the retro-mode function 
of the F10 SLO, and compared the images histologically with surgically excised fibrovascular 
membrane from two cases. In PDR, neovascular vessels in fibrovascular membrane were clearly 
seen with the retro-mode, even after IVB and without blood flow. The F10 SLO may be useful 
in evaluating neovascular vessels in fibrovascular membrane in PDR and for determining the 
precise retinal changes in diabetic retinopathy.
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Introduction
Recent clinical trials of the intravitreal injection of bevacizumab (Avastin®, Roche, 
Reinach, Switzerland) (IVB) have shown excellent results in the treatment of angio-
genic pathologies including proliferative diabetic retinopathy (PDR). It has been 
reported that IVB significantly decreases bleeding from the vessels of the fibrovascular 
membrane during vitrectomy in PDR, and IVB has also been reported to be effective 
in the regression of new vessels in PDR.1–3
The F10 (Nidek, Gamagori, Japan) is a new commercially available scanning 
laser confocal ophthalmoscope (SLO) that can perform multiple functions including 
fluorescein angiography, indocyanine green angiography, fundus   autofluorescence, 
retro-mode imaging, and dark-field mode imaging. In the dark-field mode with a 
central stop, scattered light from the deeper layers of the retina silhouettes structural 
abnormalities. In contrast, the retro-mode of the F10 SLO uses an infrared laser and an 
aperture with a modified central stop that is displaced laterally from the confocal light 
path. This optical arrangement allows for a clearer and pseudo-3-dimensional image, 
and is a new method of detecting abnormalities in the retina, such as cystoid macular 
edema4 or myopic retinoschisis.5 However, to our knowledge, no previous report has 
examined the fibrovascular membrane in PDR with the retro-mode.
Accordingly, we used the new indirect viewing system of the retro-mode func-
tion of the F10 SLO for noninvasive evaluation of PDR pathologies before and after 
IVB, and compared the images histologically with surgically excised fibrovascular 
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Cases and findings
Case 1 (Figure 1)
A 52-year-old man with a history of PDR in the left eye 
was examined. Best corrected visual acuity (BCVA) in 
this eye was 20/300. Fundus examination disclosed very 
severe fibrovascular proliferation throughout the posterior 
pole (Figure 1A). Interestingly, in the retro-mode imaging 
with the F10 SLO, the neovascular vessels in the fibrovas-
cular membrane were clearly observed, as in angiography. 
  However, the outline of the fibrovascular membrane itself 
was not clear (Figure 1B). Three days after 1.25 mg of 
IVB, fundus examination disclosed regression of most of 
the new vessels in the significantly contracted fibrovascular 
membrane, consistent with previous reports6,7 (Figure 1C). 
Surprisingly, most neovascular vessel structures in the 
fibrovascular membrane were still clearly observed in the 
retro-mode image (Figure 1D).
Case 2 (Figure 2)
A 39-year-old man with a history of PDR and vitreous hem-
orrhage in the right eye was examined. BCVA in this eye 
was 20/100. Fundus examination disclosed severe fibrovas-
cular proliferation around the optic nerve head (  Figure 2A). 
  Similarly to Case 1, neovascular vessels were clearly 
observed in the fibrovascular membrane with the retro-mode 
imaging function of the F10 SLO (Figure 2B). Two days after 
1.25 mg of IVB, fundus examination disclosed regression of 
most of the new vessels. However, in the retro-mode image, 
neovascular vessels were still observed in the fibrovascular 
membrane (Figure 2C).
To determine the morphological changes in structure of 
the neovascular vessels after IVB, we prepared formalin-
fixed paraffin embedded sections from surgically excised 
fibrovascular membrane 2 days after IVB in this case. 
Staining of the neovascular tissue with hematoxylin-eosin 
disclosed that many neovascular capillaries were still pres-
ent, but that only large vessels contained red blood cells 
(Figure 2D).
Discussion
Using the retro-mode imaging function of the F10-SLO, 
we observed regression of most new vessels in the 
significantly contracted fibrovascular membrane 2 or 
3 days after IVB. Recent reports have described the 
application of IVB in treating ocular neovascular disorders 
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Figure 1 Case 1. A 52-year-old man with very severe fibrovascular proliferation 
throughout the posterior pole (A). In the retro-mode image, neovascular vessels in 
the fibrovascular membrane were clearly observed (B). Three days after intravitreal 
bevacizumab (IVB), most new vessels had regressed in the significantly contracted 
fibrovascular  membrane  (C).  Neovascular  vessel  structures  were  still  clearly 
observed in the retro-mode image after IVB (D). Arrows and arrowheads indicate 
the same neovascular vessels across images.
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Figure 2 Case 2. A 39-year-old man with severe fibrovascular proliferation around 
the  optic  nerve  head  (A).  Neovascular  vessels  in  the  fibrovascular  membrane 
were clearly observed in the retro-mode image (B). Two days after intravitreal 
bevacizumab (IVB), most of the new vessels had regressed. However, in the retro-
mode imaging, neovascular vessel structures were still observed (C). Arrows and 
arrowheads indicate same neovascular vessels in the different images. Staining of 
the neovascular tissue from this case with hematoxylin-eosin disclosed that many 
neovascular capillaries were still present (arrowheads), but that only large vessels 
contained red blood cells (arrows) (D).Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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retro-mode image of NV in PDr after IVB
including PDR.8–10 IVB has also been reported to be effective in 
causing the regression of new vessels in PDR.1–3 Adjunctive 
use of intravitreal bevacizumab for severe PDR before 
vitrectomy significantly decreased bleeding from the vessels 
of the fibrovascular membrane during the vitrectomy.6,7 
In case 2 of our study, vitreous surgery was successfully 
performed and fibrovascular membrane was excised for 
formalin-fixed paraffin embedded sections 2 days after IVB. 
These observations suggest that our methods for IVB were 
appropriate and that 2 or 3 days might be long enough for 
neovascular vessels to regress, since Arevalo et al11 reported 
that 5.2% of PDR cases with IVB developed tractional retinal 
detachment 3 to 30 days after IVB.
We investigated noninvasive evaluation of PDR 
pathologies before and after IVB using the new indirect 
viewing system of the retro-mode function of the F10 
SLO, and compared the images histologically with surgi-
cally excised fibrovascular membrane from one case. In 
previous reports,4 distribution of the cystoid spaces was 
clearly shown on topographic imaging in diabetic macular 
edema with the retro-mode imaging function of the F10 
SLO. Optical coherence tomography has been especially 
useful in evaluating the depth distribution of cystoid 
spaces. However, the horizontal distribution was more 
easily assessed by retro-mode imaging, suggesting that the 
two technologies may be complementary.4 In our cases of 
PDR, neovascular vessels in fibrovascular membrane were 
clearly seen with the retro-mode, even after IVB and with-
out blood flow. Accordingly, the F10 SLO may be useful in 
evaluating neovascular vessels in fibrovascular membrane 
in PDR and for determining the precise retinal changes 
in diabetic retinopathy. In previous reports, neovascular 
vessels without blood flow1,3 and apoptotic cells on the 
regressing vascular walls2 were observed histologically 
after IVB. In our study, staining of the neovascular tissue 
with hematoxylin-eosin disclosed that many neovascular 
capillaries were still present, but that only large vessels 
contained red blood cells (shown in Figure 2). Our find-
ings of neovascular vessel structures after IVB may be the 
same as these previously reported regressing neovascular 
vessels without blood flow.
Although our study suggests that the F10 SLO is use-
ful in evaluating regressing neovascular vessels, there are 
several limitations to this study. First, our small sample size 
was small: only two cases were examined, and only one 
underwent histological examination. Second, the F10 SLO 
could not detect vascular permeability such as the vascular 
leakage in retinal and neovascular vessels usually observed 
in active PDR when examined with fluorescein angiography. 
In PDR with dense media opacity such as that caused by 
vitreous hemorrhage, F10 SLO could not be used for fundus 
examination. The resolution of F10 SLO is not high enough 
to visualize capillary vessels. These technical limitations of 
the F10 SLO indicate that it may be most useful in conjunc-
tion with other imaging techniques.
In conclusion, we determined the usefulness of the new 
indirect viewing system of the retro-mode function of the F10 
SLO for noninvasive evaluation of PDR pathologies before 
and after IVB. We demonstrated that the F10 SLO clearly 
demonstrated the neovascular vessels. Use of an SLO, such 
as the F10, may provide a unique detailed observation of 
retinal diseases such as PDR.
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